Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 749-754

  O'Connor, Nigel ^a   Borley, Ann ^a  

^a ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

Author keywords

ABLC; Adverse events; Audit; Hydrocortisone; Premedication

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CHLORPHENIRAMINE MALEATE; HYDROCORTISONE; PARACETAMOL; PETHIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVERSE DRUG REACTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DYSPNEA; FEMALE; GENDER; GROUPS BY AGE; HUMAN; HYPOTENSION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PREDICTOR VARIABLE; PREMEDICATION; PROSPECTIVE STUDY; RIGOR; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 67649363815     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902752753     Document Type: Conference Paper

References (15)

1. Barnes RA. Early diagnosis of fungal infection in immunocompromised patients. J Antimicrob Chemother 2008;61(Suppl 1):i3-i
2. Johnson MD, Kleinberg M, Danziger L, et al. Pharmacoeconomics of antifungal pharmacotherapy - challenges and future directions. Expert Opin Pharmacother 2005;6:2617-2632 (Pubitemid 41824377)
3. Knapp KM, Flynn PM. Newer treatments for fungal infections. J Support Oncol 2005;3:290-298 (Pubitemid 41167641)
4. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55:809-818 (Pubitemid 43974685)
5. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396 (Pubitemid 28270170)
6. Martino R, Subira M, Sureda A, et al. Amphotericin B lipid complex at 3mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999;44:569-572 (Pubitemid 29490633)
7. Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex for the treatment of confirmed or presumed fungal infections in immunocompromised patients with haematologic malignancies. Bone Marrow Transplant 1997;20:39-43 (Pubitemid 27341601)
8. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-1320 (Pubitemid 36677281)
9. Furebring M, Öberg G, Sjölin J. Side-effects of amphotericin B lipid complex (ABLC) in the Scandinavian population. Bone Marrow Transplant 2000;25:341-343 (Pubitemid 30103029)
10. Grasela TH, Goodwin SD, Walawander MK, et al. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990;10:341-348 (Pubitemid 20386852)
11. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infec Dis 1995;20:755-761
12. Kuti J, Kotapati S, Williams P, et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22:301-310 (Pubitemid 38553701)
13. Wingard JR, White MH, Anaissie E, et al. A randomised, double blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropaenia. Clin Infect Dis 2000;31:1155-1163 (Pubitemid 32295443)
14. Subira M, Martino R, Gomez L, et al. Low dose amphotericin B lipid complex vs conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with haematologic malignancies - a randomised, controlled trial. Eur J Haematol 2004;72:342-347 (Pubitemid 38520732)
15. Pappas PG. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis 2005;40:S379-83 (Pubitemid 40563294)